Patent · US Active

Markers for the prediction of outcome of anthracycline treatment

US10053735B2 · kind B2 · utility

0Cited by

9References

12Claims

0Family size

Assignee

THERAWIS DIAGNOSTICS GMBH · DE

Inventors

John Foekens · Capelle aan den IJssel, NL
John W. Martens · Rotterdam, NL
Serenella Eppenberger-Castori · Riehen, CH
Vincent Vuaroqueaux · Hésingue, FR
Frederique Spyratos · La Celle-Saint-Cloud, FR
Nadia Harbeck · Otterfing, DE
Manfred Schmitt · Munich, DE
Heinz Hoefler · Munich, DE
Sabine Maier · Brussels, BE
Gunter Weiss · Offenbach, DE
Ralf Lesche · Berlin, DE
Thomas Hildmann · Berlin, DE
Achim Plum · Berlin, DE

Key dates

Filing date	Sep 21, 2006
Grant date	Aug 21, 2018
Priority date	—
Expiry date	Dec 20, 2030

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/16
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to methods for predicting the outcome of anthracycline treatment of cell proliferative disorder patients. This is achieved by determining the expression level of at least one gene selected from the group consisting of PITX2; TFF1 and PLAU. The invention also relates to sequences, oligonucleotides and antibodies which can be used within the described methods.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.